We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Live Cell Imaging Ready to Transform Disease Diagnostics and Drug Discovery

By LabMedica International staff writers
Posted on 31 Mar 2014
Print article
Breakthroughs in fluorescent applications, electronics, optics, and molecular biology have made live cell imaging technologies more accessible to life scientists trying to better understand biologic dynamics and visualize cellular events in living organisms, according to recent market research. The introduction of “omics” technologies and nanotechnologies into mainstream medicine has already enabled commercial lab-on-a-chip microfluidics systems that analyze cells, DNA, RNA, and proteins. As live cell imaging evolves, it will become a key player in disease diagnostics and drug discovery processes.

New analysis from Frost & Sullivan (Mountain View, CA, USA), an international growth consultancy company, found that live cell imaging technologies will have a large number of niche applications in cancer research, cell biology, developmental biology, and neuroscience. Currently available technologies include live cell-based tests systems and molecular models including high-resolution imaging systems.

“The principal challenges to successful live cell imaging are microscopic settings optimization, fluorescent components selection, and culture environment maintenance,” said technical insights senior research analyst Cecilia Van Cauwenberghe. “Parallel advances in the field of cell culturing will also be critical to ensure accurate, real-time results.”

Utilizing live cell imaging along with fixed cell tests before the former totally replaces the latter, will lower costs and lessen throughput times. Equipment combining microscopes with cell culture incubators is already being marketed, facilitating affordable three-dimensional (3D), real-time assessment, multiplexing, and automation capabilities.

Tightly integrated systems can provide new benchmarks of precision and degrees of efficiency for the study of individual and small groups of live cells. They will enable innovative new ways for multiple cell analysis, simultaneous processing, and multi-day time lapse live cell imaging. However, it is essential that government patent systems protect these innovations, especially since new players in the market emerge from different start points. Similarly, measures must be taken to reduce uncertainty regarding reimbursements, and to establish frameworks assuring balance among tier I companies, small and medium enterprises, and start-ups developing innovative technologies.

“Intellectual property regimes promoting integration between academia and industry in order to deliver new solutions are necessary,” concluded Ms. Cauwenberghe. “Drug producers must collaborate with other stakeholders to translate live cell imaging innovations into clinically meaningful tests that can be used for diagnosis, prognosis and drug development.”

Related Links:

Frost & Sullivan


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more